A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
about
The current state of adverse event reporting in hemophilia.Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.A public health approach to the prevention of inhibitors in hemophilia.National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meetingComparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutationsMeeting the emerging public health needs of persons with blood disorders.Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening.Improving the performance of factor VIII inhibitor tests in hemophilia A.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system.The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.Laboratory testing for factor inhibitors.Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective.New findings on inhibitor development: from registries to clinical studies.Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.Impact of inhibitors on hemophilia A mortality in the United States.Identification of patients with congenital hemophilia in a large electronic health record database.Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.
P2860
Q30239952-23492AB7-CAB7-4BA0-BFED-714C0DC8D1C3Q35248264-FFF2D533-073C-436E-BED2-3C59FF526B78Q35747998-016276FB-CE1E-4AD4-A1F5-3AB6DC3AFB61Q35755679-CD89DE27-B856-42FB-A523-11DF2D92DD8AQ35771007-0730CA53-5738-42C3-9D69-2DFDA0BAB6CCQ35881803-4B26C9DB-23F6-4445-B96F-549E11CD9A25Q36057008-C3CD0515-0A99-42BA-8411-19F094E9D65EQ36274480-BF407442-3E51-47C3-BFC1-E879324FCEC6Q36477040-503EA500-9B63-4F4F-AB0F-3D17E071E55DQ37185097-FD043C58-C5B4-4095-9E6C-923FC4F0D342Q37330601-E770D4C6-72CC-40B4-A967-957A9D93B7B9Q37606315-E97AAE83-5C5C-4D88-B6C4-A97C69D941EBQ38206857-DD87E3F5-9134-460E-ABB4-84C548501F0BQ38955500-31046A38-9C67-48A9-91DB-7484D7EEBC9DQ39042987-DF72A8E4-0B4E-4E6D-8E69-F2353BCF4ADEQ39512337-F827D59B-284B-47A1-9508-DA88C323867AQ41524981-73858407-795D-4C02-95C1-E03B9E6301B4Q41633798-58A014D7-600C-49E3-BE25-9F4151FF50FAQ45870641-C7D41133-2CBC-47C4-84E2-0C264D2DBE4BQ49817555-6428EAA4-F8DA-4031-8F43-27501944F9D3
P2860
A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A study of prospective surveil ...... mophilia in the United States.
@ast
A study of prospective surveil ...... mophilia in the United States.
@en
type
label
A study of prospective surveil ...... mophilia in the United States.
@ast
A study of prospective surveil ...... mophilia in the United States.
@en
prefLabel
A study of prospective surveil ...... mophilia in the United States.
@ast
A study of prospective surveil ...... mophilia in the United States.
@en
P2093
P2860
P356
P1433
P1476
A study of prospective surveil ...... mophilia in the United States.
@en
P2093
C L Kempton
Haemophilia Inhibitor Research Study Investigators
J M Soucie
M J Manco-Johnson
P L Bockenstedt
P2860
P304
P356
10.1111/HAE.12302
P577
2013-11-22T00:00:00Z